Press release
Opioid Withdrawal Syndrome Pipeline Analysis, 2025 by DelveInsight | Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Aphios Pharmaceutical
Opioid Withdrawal Syndrome Pipeline Analysis
DelveInsight reports that the Opioid Withdrawal Syndrome pipeline includes over 4 key companies actively developing more than 4 therapeutic candidates.
Opioid Withdrawal Syndrome Overview:
Opioid Withdrawal Syndrome is a potentially serious condition that arises from dependence on opioids, a class of drugs often prescribed for severe pain. The syndrome occurs when opioid use is abruptly reduced or discontinued after prolonged and heavy use, triggering a variety of withdrawal symptoms. Common symptoms include anxiety, chills or goosebumps, restlessness, insomnia, frequent yawning, runny nose, watery eyes, fever, nausea, vomiting, and diarrhea, among others.
The locus coeruleus, located at the base of the brain, plays a central role in triggering these withdrawal symptoms. Current treatment approaches for Opioid Withdrawal Syndrome include gradual tapering of full opioid agonists such as methadone, short-term use of partial mu-opioid agonists like buprenorphine, and detoxification protocols using opioid antagonists such as naltrexone and naloxone.
Download our report @ https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Opioid Withdrawal Syndrome Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Opioid Withdrawal Syndrome Therapeutics Market.
Key Takeaways from the Opioid Withdrawal Syndrome Pipeline Report
*
DelveInsight's report on the Opioid Withdrawal Syndrome (OWS) pipeline highlights a focused space, with over 4 companies actively developing more than 4 therapeutic candidates.
*
In May 2018, the FDA approved Lucemyra (lofexidine hydrochloride), the first non-opioid medication aimed at easing withdrawal symptoms in adults discontinuing opioid use. Lucemyra works by reducing norepinephrine release, a neurotransmitter linked to withdrawal symptoms. While it can lessen symptom severity, it does not completely prevent them and is approved for treatment durations of up to 14 days.
*
Leading companies advancing OWS therapies include Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Aphios Pharmaceutical, and others.
*
Notable pipeline candidates in development include CHF-6563, BXCL501, among others.
Opioid Withdrawal Syndrome Pipeline Analysis
The Opioid Withdrawal Syndrome pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Opioid Withdrawal Syndrome Market.
*
Categorizes Opioid Withdrawal Syndrome therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Opioid Withdrawal Syndrome drugs under development based on:
*
Stage of development
*
Opioid Withdrawal Syndrome Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Opioid Withdrawal Syndrome Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Opioid Withdrawal Syndrome Licensing agreements
*
Funding and investment activities supporting future Opioid Withdrawal Syndrome market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Opioid Withdrawal Syndrome Emerging Drugs
*
CHF-6563: Chiesi Farmaceutici S.p.A.
*
BXCL501: BioXcel Therapeutics
Opioid Withdrawal Syndrome Companies
More than four leading companies are actively developing treatments for Opioid Withdrawal Syndrome, with Chiesi Farmaceutici S.p.A. advancing a drug candidate to the most advanced stage to date-Phase II clinical trials.
DelveInsight's report covers around 4+ products under different phases of Opioid Withdrawal Syndrome clinical trials like
*
Opioid Withdrawal Syndrome Late stage Therapies (Phase III)
*
Opioid Withdrawal Syndrome Mid-stage Therapies (Phase II)
*
Opioid Withdrawal Syndrome Early-stage Therapies (Phase I)
*
Opioid Withdrawal Syndrome Pre-clinical and Opioid Withdrawal Syndrome Discovery stage Therapies
*
Opioid Withdrawal Syndrome Discontinued & Inactive Therapies
Opioid Withdrawal Syndrome pipeline report provides the Opioid Withdrawal Syndrome therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Opioid Withdrawal Syndrome Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Opioid Withdrawal Syndrome Therapies and Key Opioid Withdrawal Syndrome Companies: Opioid Withdrawal Syndrome Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Opioid Withdrawal Syndrome Pipeline Therapeutic Assessment
- Opioid Withdrawal Syndrome Assessment by Product Type
- Opioid Withdrawal Syndrome By Stage
- Opioid Withdrawal Syndrome Assessment by Route of Administration
- Opioid Withdrawal Syndrome Assessment by Molecule Type
Download Opioid Withdrawal Syndrome Sample report to know in detail about the Opioid Withdrawal Syndrome treatment market @ Opioid Withdrawal Syndrome Therapeutic Assessment [https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Opioid Withdrawal Syndrome Current Treatment Patterns
4. Opioid Withdrawal Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Opioid Withdrawal Syndrome Late-Stage Products (Phase-III)
7. Opioid Withdrawal Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Opioid Withdrawal Syndrome Discontinued Products
13. Opioid Withdrawal Syndrome Product Profiles
14. Opioid Withdrawal Syndrome Key Companies
15. Opioid Withdrawal Syndrome Key Products
16. Dormant and Discontinued Products
17. Opioid Withdrawal Syndrome Unmet Needs
18. Opioid Withdrawal Syndrome Future Perspectives
19. Opioid Withdrawal Syndrome Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Opioid Withdrawal Syndrome Pipeline Reports Offerings [https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=opioid-withdrawal-syndrome-pipeline-analysis-2025-by-delveinsight-chiesi-farmaceutici-spa-bioxcel-therapeutics-aphios-pharmaceutical]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Opioid Withdrawal Syndrome Pipeline Analysis, 2025 by DelveInsight | Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Aphios Pharmaceutical here
News-ID: 4165695 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Opioid
Rising Opioid Use For Pain Management Fuels Growth In Opioid-Induced Constipatio …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Opioid-Induced Constipation Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for treatment of opioid-induced constipation has seen a substantial growth recently. It is expected to escalate from a solid $1.78 billion in 2024 to an impressive $1.9 billion in 2025, exhibiting…
Growing Number Of Opioid Addiction Cases: Strategic Insights Driving Opioid Use …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Opioid Use Disorder (OUD) Market Size By 2025?
The market size for opioid use disorder (OUD) has experienced a quick expansion in the past few years. The growth is projected to rise from $3.96 billion in 2024 to $4.39 billion in 2025, boasting a compound…
Key Influencer in the Opioid-Induced Constipation Treatment Market 2025: Rising …
What combination of drivers is leading to accelerated growth in the opioid-induced constipation treatment market?
The rise in opioid administration for cancer and non-cancer pain is expected to drive the growth of the opioid-induced constipation (OIC) treatment market. Opioids are commonly used for managing moderate to severe pain, but they can cause constipation. OIC treatments are vital for improving the quality of life for patients on opioids, allowing them to maintain…
Top Factor Driving Opioid Use Disorder (OUD) Market Growth in 2025: Growing Numb …
How Are the key drivers contributing to the expansion of the opioid use disorder (oud) market?
The rise in instances of opioid dependency is set to fuel the expansion of the opioid use disorder (OUD) market. Opioid dependency defines a health concern marked by habitual and uncontrolled opioid consumption which negatively impacts health. These opioids can generate feelings of bliss and relief from pain, but continued usage often results in tolerance…
What's Driving the Opioid-Induced Constipation Treatment Market 2025-2034: Risin …
What Are the Projections for the Size and Growth Rate of the Opioid-Induced Constipation Treatment Market?
The market size for treatments of constipation caused by opioids has seen robust growth lately. The forecasted growth indicates an increase from $1.78 billion in 2024 to $1.9 billion in 2025, representing a compound annual growth rate (CAGR) of 7.0%. This past growth is associated with a growing elderly population, individualized treatments for OIC, the…
MEDICAL MARIJUANA AND THE OPIOID CRISIS
Marijuana from the Cannabis plant is classified as a psychoactive drug used for medical or recreational purposes. Although it has been used for decades, in the U.S., it is still illegal under federal law to use and possess marijuana.
Get PDF Sample Brochure of this report at: https://decisionmarketreports.com/request-sample/1247622
Nevertheless, at the state level, policies regarding the medical and recreational use of Cannabis vary greatly, and in many states conflict significantly with federal…
